DNA and replicative machinery

The DNA and replicative machinery represent a fundamental therapeutic target encompassing the DNA molecule itself and the coordinated assembly of proteins, known as the replisome, required for genome duplication (Nature Reviews Molecular Cell Biology, 2017). This machinery includes essential enzymes such as DNA polymerases, helicases, and topoisomerases that work together to ensure the high-fidelity copying of genetic material during the S-phase of the cell cycle (NIH, 2023). In oncology, this target is exploited because cancer cells exhibit uncontrolled proliferation and a heightened reliance on efficient DNA synthesis to maintain their genomic integrity (Nature Reviews Cancer, 2021). Drugs targeting this system include alkylating agents that chemically modify DNA, antimetabolites that interfere with nucleotide metabolism, and specific enzyme inhibitors that stall the replication fork (StatPearls, 2023). Beyond cancer, the replicative machinery of viruses and bacteria is a primary target for anti-infective agents, such as nucleoside analogs and quinolones, which selectively disrupt pathogen replication (PubMed, 2020). While highly effective, therapies targeting DNA replication often face challenges related to off-target toxicity in rapidly dividing healthy tissues and the development of complex resistance mechanisms (Journal of Clinical Oncology, 2022).

Other names

ReplisomeDNA replication complexDNA synthesis machineryDNA replication apparatus

Inhibition of DNA synthesis via DNA cross-linking, intercalation, antimetabolite-mediated chain termination, and inhibition of enzymes such as DNA polymerase and topoisomerase.